Last reviewed · How we verify

NCT06704360: EVRPSC

Efficacy and Safety of Immersive Virtual Reality for Post-stroke Cognitive Impairment

Not yet recruiting NA Last updated 26 November 2024
What this trial tests

NA trial testing immersive VR pathfinding training in Stroke in 40 participants. Not yet recruiting.

Timeline
1 December 2024
Primary endpoint
1 November 2025
1 December 2025

Quick facts

Lead sponsorDingqun Bai
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment40
Start date1 December 2024
Primary completion1 November 2025
Estimated completion1 December 2025

Drugs / interventions tested

Conditions studied

Sponsor

Dingqun Bai

Who can join

Adults 18 to 85, any sex, with Stroke or Cognitive Decline. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-blind randomized controlled trial to evaluate the efficacy and safety of immersive virtual reality for post-stroke cognitive impairment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Dingqun Bai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06704360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing